Page last updated: 2024-11-06

aromasil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID60198
CHEMBL ID1200374
CHEBI ID4953
SCHEMBL ID6215
MeSH IDM0478104

Synonyms (121)

Synonym
AC-2171
AB00639936-10
AB00639936-08
AKOS015840113
aromasin (pharmacia upjohn)
nsc713563
nsc-713563
nikidess
exe ,
6-methyleneandrosta-1,4-diene-3,17-dione
exemestano [inn-spanish]
fce-24304
exemestane [usan:inn:ban]
c20h24o2
androsta-1,4-diene-3,17-dione, 6-methylene-
exemestanum [inn-latin]
aromasin
hsdb 7463
fce 24304
CURATOR_000009 ,
MLS001424062
C08162
107868-30-4
exemestane ,
smr000466314
MLS000759419
DB00990
cpd000466314
6-methylenandrosta-1,17-dione
aromasin (tn)
exemestane (jan/usp/inn)
D00963
aromasil
examestane
aromasine
HMS2051J04
exemestano
exemestanum
CHEBI:4953 ,
(8r,9s,10r,13s,14s)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione
fce24304
pnu-155971
CHEMBL1200374
nsc-758907
6-methylene-androsta-1,4-diene-3,17-dione
A801772
(8alpha,10alpha,13alpha)-6-methylideneandrosta-1,4-diene-3,17-dione
exm ,
cas-107868-30-4
dtxcid003037
dtxsid5023037 ,
tox21_111499
ccris 9351
nsc 758907
ny22hmq4bx ,
unii-ny22hmq4bx
pnu 155971
CCG-100995
BCP9000676
bdbm50398447
BCPP000235
BCP0726000226
exemestane [orange book]
exemestane [hsdb]
exemestane [usan]
exemestane [inn]
exemestane [jan]
exemestane [vandf]
exemestane [who-dd]
exemestane [mi]
exemestane [usp-rs]
exemestane [usp monograph]
exemestane [ep monograph]
exemestane [mart.]
S1196
AKOS015895161
gtpl7073
AB00639936-06
HY-13632
CS-1766
(8r,9s,10r,13s,14s)-10,13-dimethyl-6-methylene-7,8,9,11,12,13,15,16-octahydro-6h-cyclopenta[a]phenanthrene-3,17(10h,14h)-dione
NC00245
E0941
SCHEMBL6215
NCGC00271596-03
tox21_111499_1
exemestane, aromasin
KS-5136
6-methylenandrost-1,4-dien-3,17-dione
6-methylen-androst-1,4-diene-3,17-dione
BFYIZQONLCFLEV-DAELLWKTSA-N
AB00639936-09
(8r,9s,10r,13s,14s)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3h-cyclopenta[a]phenanthrene-3,17(6h)-dione
AB00639936_11
(1s,2r,10r,11s,15s)-2,15-dimethyl-8-methylidenetetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,14-dione
pnu155971
SR-01000759393-4
sr-01000759393
exemestane, united states pharmacopeia (usp) reference standard
exemestane, pharmaceutical secondary standard; certified reference material
exemestane, european pharmacopoeia (ep) reference standard
exemestane, >=98% (hplc)
exemestane for system suitability, european pharmacopoeia (ep) reference standard
androsta-1,4-diene-3,17-dione, 6-methylene-; 6-methyleneandrosta-1,4-diene-3,17-dione; aromasil; aromasin; exemestane; fce 24304
exemestane(fce 24304)
HMS3713H12
exemestane; aromasin
Q418819
AS-31053
BCP23353
BRD-K33425534-001-12-5
exemestane (ep monograph)
exemestano (inn-spanish)
exemestane (usp-rs)
l02bg06
exemestanum (inn-latin)
exemestane (usp monograph)
exemestane (mart.)
CS-0694867
exemestane (standard)
HY-13632R

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The most common adverse events, including those not related to treatment, were mild to moderate headache (44% of patients), dizziness (33%), nausea (33%), hot flushes (30%) and tumor-related pain (30%)."( Safety, activity and estrogen inhibition by exemestane in postmenopausal women with advanced breast cancer: a phase I study.
de Belder, K; di Salle, E; Lanzalone, S; Lobelle, JP; Ornati, G; Paridaens, R; Polli, A; Thomas, J; Vermeiren, P; Wildiers, J; Zurlo, MG, 1998
)
0.3
" The incidence and severity of adverse events were assessed by physical examination and patient reporting."( Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004
)
0.32
" All drug-related adverse events were grades 1 or 2; none was unexpected."( Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Asnis, AG; Duncan, B; Francis, D; Hortobagyi, GN; Rivera, E; Schaaf, LJ; Valero, V, 2004
)
0.32
" Tamoxifen treatment is limited to 5 years because of the development of de novo and acquired resistance, and an ongoing risk of adverse events, including endometrial cancer, thromboembolic events, and gynecological symptoms with long-term use."( Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
Conte, P; Frassoldati, A,
)
0.13
" Generally, adverse events with AIs are predictable and manageable, whereas tamoxifen may be associated with life-threatening events in a minority of patients."( Safety of aromatase inhibitors in the adjuvant setting.
Perez, EA, 2007
)
0.34
" The rates of severe taxane-related toxic effects and thrombocytopenia, although low overall, are significantly increased with the dose-dense sequential regimen."( Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00.
Bafaloukos, D; Briasoulis, E; Dafni, U; Dimitrakakis, K; Dimopoulos, AM; Fountzilas, G; Gogas, H; Kalofonos, HP; Karanikiotis, C; Karina, M; Linardou, H; Makrantonakis, P; Markopoulos, C; Papadimitriou, C; Papakostas, P; Pectasides, D; Pisanidis, N; Polichronis, A; Samantas, E; Skarlos, D; Stathopoulos, GP; Tzorakoeleftherakis, E; Varthalitis, I; Xiros, N, 2008
)
0.35
"We performed a case-control genome-wide association study (GWAS) to identify single nucleotide polymorphisms (SNPs) associated with musculoskeletal adverse events (MS-AEs) in women treated with aromatase inhibitors (AIs) for early breast cancer."( Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM, 2010
)
0.36
" Cases were matched to two controls and were defined as patients with grade 3 or 4 MS-AEs (according to the National Cancer Institute's Common Terminology Criteria for Adverse Events v3."( Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM, 2010
)
0.36
" These findings provide a focus for further research to identify patients at risk for MS-AEs and to explore the mechanisms for these adverse events."( Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors.
Batzler, A; Chapman, JA; Ellis, MJ; Flockhart, DA; Goetz, MP; Goss, PE; Ingle, JN; Jenkins, GD; Kubo, M; Liu, M; Mushiroda, T; Nakamura, Y; Pater, J; Pritchard, KI; Rohrer, DC; Schaid, DJ; Shepherd, L; Stearns, V; Wang, L; Weinshilboum, RM, 2010
)
0.36
"Exemestane is a safe drug due to its steroidal structure, which blocks aromatase at a different site to nonsteroidal AIs (eg."( Drug safety evaluation of exemestane.
Lintermans, A; Neven, P; Paridaens, R, 2011
)
0.37
"Health-related quality of life (HRQOL), symptoms of depression, and adverse events (AEs) were compared between Japanese postmenopausal patients with hormone-sensitive breast cancer (BC) who received adjuvant tamoxifen, exemestane, or anastrozole in an open-labeled, randomized, multicenter trial designated as the National Surgical Adjuvant Study of Breast Cancer (N-SAS BC) 04 substudy of the Tamoxifen Exemestane Adjuvant Multinational (TEAM) trial."( Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-
Hozumi, Y; Ohashi, Y; Ohsumi, S; Shimozuma, K; Suemasu, K; Takehara, M; Takei, H, 2012
)
0.38
"Many adverse events (AEs) associated with aromatase inhibitors (AIs) involve symptoms related to the depletion of circulating estrogens, and may be related to efficacy."( Relationship between specific adverse events and efficacy of exemestane therapy in early postmenopausal breast cancer patients.
Bartlett, JMS; Dirix, LY; Fontein, DBY; Gelderblom, H; Guchelaar, HJ; Hille, ETM; Houtsma, D; Meershoek-Klein Kranenbarg, E; Nortier, JWR; Paridaens, R; Putter, H; Seynaeve, C; van de Velde, CJH, 2012
)
0.38
"Specific adverse events (AEs) associated with endocrine therapy and related to depletion or blocking of circulating estrogens may be related to treatment efficacy."( Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: an international tamoxifen exemestane adjuvant multinational trial analysis.
Bartlett, JM; Fontein, DB; Hadji, P; Hasenburg, A; Hille, ET; Hozumi, Y; Jones, SE; Kranenbarg, EM; Markopoulos, C; Nortier, JW; Paridaens, RJ; Putter, H; Rea, DW; Seynaeve, C; van de Velde, CJ; van de Water, W; Vannetzel, JM, 2013
)
0.39
" Although everolimus is generally well tolerated, as with most therapies administered in an advanced cancer setting, drug-related adverse events (AEs) inevitably occur."( Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Peterson, ME, 2013
)
0.39
" Adverse events (AEs) of special interest (all grades) that occurred more frequently with EVE than with PBO included stomatitis, infections, rash, pneumonitis, and hyperglycemia."( Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2.
Baselga, J; Bourgeois, H; Burris, HA; Campone, M; Csöszi, T; Dakhil, S; Gnant, M; Gonzalez Martin, A; Heng, D; Hortobagyi, GN; Ito, Y; Noguchi, S; Osborne, K; Panneerselvam, A; Piccart, M; Pritchard, KI; Puttawibul, P; Rugo, HS; Sahmoud, T; Srimuninnimit, V; Taran, T, 2013
)
0.39
"This experimental study aims to investigate whether radiotherapy (RT) plus trastuzumab (T) followed by subsequent hormonotherapy increase the cumulative toxic effect on cardiac functions in rats."( The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats.
Arsav, V; Benderli Cihan, Y, 2014
)
0.4
"At the end of the study, no loss and adverse effects were seen in any group."( The effects of hormonotherapy administered concurrent radiotherapy and trastuzumab on cardiac toxicity in rats.
Arsav, V; Benderli Cihan, Y, 2014
)
0.4
" This study estimates the costs of managing adverse events (AEs) during EVE + EXE therapy and single-agent chemotherapy in Western Europe."( Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone, M; Faust, E; Gao, H; Kageleiry, A; Signorovitch, JE; Yang, H; Zhang, J, 2014
)
0.4
" The most costly adverse event among all patients treated with EVE + EXE was anemia (on average €152 per patient)."( Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.
Campone, M; Faust, E; Gao, H; Kageleiry, A; Signorovitch, JE; Yang, H; Zhang, J, 2014
)
0.4
" Exemestane was safe and well tolerated."( Exemestane Use in Postmenopausal Women at High Risk for Invasive Breast Cancer: Evaluating Biomarkers of Efficacy and Safety.
Eng-Wong, J; Galbo, CE; Gallagher, A; Gatti-Mays, ME; Heckman-Stoddard, BM; Isaacs, C; Kallakury, B; Korde, L; Makariou, E; Reynolds, J; Singer, A; Venzon, D; Warren, R, 2016
)
0.43
" Although the pleural effusion reduced markedly after 5 weeks, stomatitis, diarrhea, melena, and interstitial pneumonia occurred as adverse events."( [An Elderly Patient with Metastatic Breast Cancer Who Developed Severe Adverse Events such as Stomatitis and Interstitial Pneumonia after Everolimus plus Exemestane Treatment].
Goto, Y; Kimura, M; Sakiyama, K; Yoshida, T, 2016
)
0.43
" The primary objective was safety of EVE plus EXE based on frequency of adverse events (AEs), and serious AEs (SAEs)."( Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, e
Bianchetti, S; Camozzi, M; Ciruelos, EM; Conte, P; Gavila, JG; Generali, D; Jerusalem, G; Lang, I; Lorizzo, K; Mardiak, J; Mariani, G; Martin, M; Michelotti, A; Montemurro, F; Naume, B; Neven, P; Simoncini, E; Tjan-Heijnen, VC, 2016
)
0.43
"Due to toxic events, everolimus dosage was reduced to 5 mg in 27% of patients."( Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P, 2016
)
0.43
"The association of everolimus and exemestane has confirmed to be a safe and effective treatment for endocrine sensitive MBC patients even in routine clinical practice."( Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P, 2016
)
0.43
"In the adjuvant setting, specific adverse events (AEs) such as vasomotor symptoms (VMS) and musculoskeletal AEs are associated with relapse-free survival in aromatase inhibitor (AI)-treated patients."( Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Charehbili, A; Fontein, DB; Kranenbarg, EM; Kroep, JR; Linn, SC; Nortier, JW; Putter, H; van de Velde, CJ, 2017
)
0.46
" Out of 240 reported adverse events, 71 were specific AEs (40 MSAEs, 31 VMSs)."( Specific adverse events are associated with response to exemestane therapy in postmenopausal breast cancer patients: Results from the TEAMIIA study (BOOG2006-04).
Charehbili, A; Fontein, DB; Kranenbarg, EM; Kroep, JR; Linn, SC; Nortier, JW; Putter, H; van de Velde, CJ, 2017
)
0.46
"1%), and adverse events (AEs) (16."( Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P, 2017
)
0.46
" Thus, it is important to assess even the potential of cumulative and additive toxic effects among the drugs."( Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.
Ascione, G; Barone, CA; Bighin, C; Bordonaro, R; Cazzaniga, ME; Cognetti, F; Foglietta, J; Frassoldati, A; Generali, D; Goffredo, F; Ionta, MT; Latini, L; Mafodda, A; Mariani, G; Michelotti, A; Minisini, AM; Molino, A; Montemurro, F; Nolè, F; Nuzzo, F; Piacentini, F; Piovano, P; Portera, G; Riccardi, F; Roila, F; Romito, S; Sartori, D; Schirone, A; Simoncini, EL; Testore, F; Vici, P, 2017
)
0.46
" Grade 3-4 adverse events (AEs) were reported in 37."( Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Cazzaniga, ME; Ciccarese, M; Clivio, L; Cursano, MC; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Piezzo, M; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Torri, V; Turletti, A; Valerio, MR; Vici, P; Zambelli, A, 2017
)
0.46
" The combination is safe and the best response could be obtained in patients receiving the full dose of EVE and/or after hormone-therapy as Fulvestrant in ABC."( Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.
Airoldi, M; Arcangeli, V; Artale, S; Atzori, F; Ballerio, A; Bianchi, GV; Blasi, L; Campidoglio, S; Cazzaniga, ME; Ciccarese, M; Clivio, L; Cursano, MC; Fabi, A; Ferrari, L; Ferzi, A; Ficorella, C; Frassoldati, A; Fumagalli, A; Garrone, O; Gebbia, V; Generali, D; La Verde, N; Maur, M; Michelotti, A; Moretti, G; Musolino, A; Palumbo, R; Piezzo, M; Pistelli, M; Porpiglia, M; Sartori, D; Scavelli, C; Schirone, A; Torri, V; Turletti, A; Valerio, MR; Vici, P; Zambelli, A, 2017
)
0.46
" Secondary outcomes were adverse events."( Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017
)
0.46
" We directly compared adverse events and found that tamoxifen produced more hot flash events than fulvestrant 250 mg."( Efficacy and safety of endocrine monotherapy as first-line treatment for hormone-sensitive advanced breast cancer: A network meta-analysis.
He, Y; Huang, Y; Wang, C; Wu, K; Zhang, J; Zheng, S, 2017
)
0.46
" The objectives of this analysis were to evaluate the safety profile of this combination in a subset of Spanish patients in the BALLET trial and to characterize grade 3 and 4 adverse events (AEs) in routine clinical practice in Spain."( Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain.
Beliera, A; Carabantes, F; Ciruelos, E; Fernández, Y; Fonseca, R; García-Sáenz, JA; Gavilá, J; Martínez de Dueñas, E; Martínez-Jáñez, N; Murillo, L; Vidal, M, 2018
)
0.48
" The most common all-grade adverse events(AEs)were stomatitis(82%) and non-infectious lung disease(27%)."( [Efficacy and Safety of Everolimus plus Exemetane in Postmenopausal Endocrine-Responsive Metastatic Breast Cancer Patients].
Kubo, H; Maeda, N; Nagano, H; Nagashima, Y; Sakamoto, K; Sato, Y; Suzuki, N; Takeda, S; Yamamoto, S, 2017
)
0.46
" The most frequent grade 3/4 adverse events were stomatitis (8."( Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial.
Decker, T; Distelrath, A; Fasching, PA; Hadji, P; Janni, W; Kreuzeder, J; Kurbacher, CM; Lüftner, D; Lux, MP; Marmé, F; Mundhenke, C; Muth, M; Quiering, C; Schneeweiss, A; Stoetzer, O; Taran, FA; Tesch, H, 2019
)
0.51
" Further studies are necessary to determine if the F-FDG PET/CT could early predict adverse effects of mTOR inhibitors."( Everolimus-induced pulmonary toxicity: Findings on 18F-FDG PET/CT imaging.
Bruna-Muraille, C; Dejust, S; Eymard, JC; Morland, D; Papathanassiou, D; Savoye, AM; Yazbek, G, 2018
)
0.48
"2%) adverse events (AEs)."( Efficacy and safety of everolimus plus exemestane in patients with HR+, HER2- advanced breast cancer progressing on/after prior endocrine therapy in routine clinical practice: Primary results from the non-interventional study, STEPAUT.
Bartsch, R; Egle, D; Gnant, M; Greil, R; Haslbauer, F; Helfgott, R; Hennebelle, M; Hock, K; Hubalek, M; Lang, A; Marth, C; Mraz, B; Öhler, L; Petru, E; Pfeiler, G; Redl, A; Steger, GG; Tinchon, C, 2020
)
0.56
" The objectives of this analysis were to provide additional information on the safety profile of this schedule depending on prior anticancer therapies and to characterize the time course of adverse events (AEs) and serious AEs (SAEs) of clinical interest throughout the study period."( Everolimus plus exemestane in hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: incidence and time course of adverse events in the phase IIIb BALLET population.
Ciruelos, E; Conte, P; Gavila, J; Generali, D; Jerusalem, G; Lang, I; Martin, M; Martínez-Serrano, MJ; Montemurro, F; Neven, P; Perelló, MF; Tjan-Heijnen, VCG, 2020
)
0.56

Pharmacokinetics

ExcerptReferenceRelevance
"In the absence of data from direct clinical comparisons, the published literature was reviewed for the clinical pharmacology, pharmacokinetic characteristics, and selectivity profiles of anastrozole, letrozole, and exemestane."( An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar, AU; Eiermann, W; Nabholtz, JM; Robertson, JF, 2002
)
0.31
" To characterize its suppression of estrogen and its pharmacokinetic (PK) properties in males, healthy eugonadal subjects (14-26 yr of age) were recruited."( Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
di Salle, E; Kwok, A; Lima, J; Lippe, B; Mauras, N; Patel, D; Rini, A, 2003
)
0.32
" Samples of plasma (to 168 h after dosing) and urine (to 72 h in study 1, or 96 h in study 2) were taken for pharmacokinetic analysis."( The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Buchan, P; Cicioni, P; Jannuzzo, MG; Poggesi, I; Rocchetti, M; Spinelli, R, 2004
)
0.32
" Clinical trials combining tamoxifen with letrozole or anastrazole have shown minor pharmacokinetic drug interactions."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
" Blood was collected for pharmacokinetic analysis after at least 4 months of receiving 20 mg tamoxifen daily."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
"There is no pharmacokinetic interaction between tamoxifen and exemestane."( Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Cleary, JF; Havighurst, TC; Hutson, PR; Love, RR; Rogers, E, 2005
)
0.33
" Pharmacokinetic and pharmacodynamic data for plasma estrogens, raloxifene, exemestane, and their metabolites were collected at the end of single-agent therapy and during combination therapy."( Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA, 2008
)
0.35
" Pharmacokinetic data have shown that, at the approved dose (250 mg/month), it takes approximately 3-6 months for fulvestrant to reach steady-state levels."( Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
McCormack, P; Sapunar, F, 2008
)
0.35
" Plasma fulvestrant concentrations were determined by highperformance liquid chromatography-mass spectrometry, and pharmacokinetic parameters were estimated with nonlinear mixed-effects modeling."( Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
McCormack, P; Sapunar, F, 2008
)
0.35
"Thirty-seven patients receiving fulvestrant were enrolled into the pharmacokinetic substudy, and 269 fulvestrant plasma concentrations were recorded."( Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
McCormack, P; Sapunar, F, 2008
)
0.35
"Steady-state plasma levels were attained within the first month of treatment with fulvestrant LD, in line with the predictions of the pharmacokinetic model."( Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
McCormack, P; Sapunar, F, 2008
)
0.35
" Everolimus has a favorable pharmacokinetic (PK) profile in early breast cancer studies."( Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Awada, A; Barthélémy, P; Gombos, A, 2015
)
0.42
"This review article focuses on the biological rationale of using everolimus in breast cancer and on latest advances in the field of everolimus-based combinations with an emphasis on the PK and pharmacodynamic parameters of the drug throughout different studies."( Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Awada, A; Barthélémy, P; Gombos, A, 2015
)
0.42

Compound-Compound Interactions

ExcerptReferenceRelevance
" Plasma estrogen concentrations were suppressed below the lower limit of detection by exemestane as monotherapy and when administered in combination with raloxifene."( Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Asnis, A; Borgen, P; Dang, C; Dickler, MN; Duncan, BA; Heerdt, A; Hudis, C; Lake, D; Moasser, M; Norton, L; Panageas, K; Poggesi, I; Robson, M; Traina, TA, 2008
)
0.35
"Forty postmenopausal women with hormone-responsive advanced breast cancer received intramuscular injection of fulvestrant 250 mg every 28 days in combination with daily exemestane 25 mg until disease progression."( Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer.
Layman, R; Li, X; Mrózek, E; Ottman, S; Ramaswamy, B; Schaaf, L; Shapiro, CL, 2012
)
0.38
" We investigated the tolerability and pharmacokinetics of exemestane in combination with metformin and rosiglitazone in nondiabetic overweight and obese postmenopausal women with hormone receptor-positive metastatic breast cancer."( Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.
Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC, 2013
)
0.39
"Oral everolimus (Afinitor(®)) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human epidermal growth factor receptor (HER) 2-negative advanced breast cancer in postmenopausal women after failure of treatment with letrozole or anastrozole (in the USA) or after recurrence of progression following a nonsteroidal aromatase inhibitor (AI) in women without symptomatic visceral disease (in the EU)."( Everolimus in combination with exemestane: a review of its use in the treatment of patients with postmenopausal hormone receptor-positive, HER2-negative advanced breast cancer.
Dhillon, S, 2013
)
0.39
"To study antitumor activity of triptorelin - agonist of gonadotropin-releasing hormone and exemestane - inhibitor of aromatase in combination with cisplatin on the model of receptor-positive for estrogens and progesterone malignant transplantable ascites ovarian tumor (OT); to assess tumor response to treatment and VEGF expression in tumor cells under different combinations of cytostatic and hormonal drugs."( The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Grabovoy, AN; Svintsitsky, VS; Tarasova, TO; Tkalia, IG; Vorobyova, LI, 2015
)
0.42
" Rats were distributed into 4 groups (9 rats in each group): group 1 - animals, which received combination of cisplatin and triptorelin; group 2 - rats treated with combination of cisplatin and exemestane; group 3 - animals, which were administered with combination of cisplatin, triptorelin and exemestane; group 4 - rats, which received combination of triptorelin and exemestane."( The antitumor efficacy of cisplatin in combination with triptorelin and exemestane therapy for an ovarian cancer ascites model in Wistar rats.
Grabovoy, AN; Svintsitsky, VS; Tarasova, TO; Tkalia, IG; Vorobyova, LI, 2015
)
0.42
"Palbociclib is the first cyclin-dependent kinase 4/6 inhibitor approved in the United States for HR+/HER2- advanced/metastatic breast cancer, in combination with letrozole as initial endocrine-based therapy in postmenopausal women or with fulvestrant in women with disease progression following endocrine therapy."( Comparison of palbociclib in combination with letrozole or fulvestrant with endocrine therapies for advanced/metastatic breast cancer: network meta-analysis.
Chirila, C; Colosia, A; Iyer, S; Kaye, JA; Ling, C; Mitra, D; Odom, D, 2017
)
0.46
"To explore the efficacy and safety of everolimus combined with endocrine therapy in patients with hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER-2)-negative advanced breast cancer."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13
" Of them, 54 patients were treated with everolimus combined with endocrine drugs (Everolimus group), while the other 54 patients underwent endocrine monotherapy (Control group)."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13
"Everolimus combined with endocrine therapy has significant clinical efficacy in patients with HR-positive/HER-2-negative advanced breast cancer, and can effectively improve the survival of patients with tolerable adverse reactions."( Efficacy of everolimus combined with endocrine therapy in HR-positive/HER-2-negativeadvanced breast cancer.
Chen, C; Kong, F; Lu, J; Shan, H; Song, X; Wang, L; Yuan, H,
)
0.13
" The primary objective was to determine the maximum tolerated dose (MTD)/recommended dose for expansion (RDE) of ALP in combination with EVE and in combination with EVE and exemestane (EXE) and subsequently assess safety, preliminary efficacy and effect of ALP on the pharmacokinetics of EVE and determine the magnitude of the drug-drug interaction."( Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Ajipa, O; Andre, F; Beck, JT; Blumenstein, L; Curigliano, G; Donnet, V; Fazio, N; Hubner, RA; Jhaveri, K; Lahner, H; Li, Z; Martin, M; Maur, M; Tortora, G, 2021
)
0.62
" There were no clinically relevant drug-drug interactions observed between ALP and EVE."( Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Ajipa, O; Andre, F; Beck, JT; Blumenstein, L; Curigliano, G; Donnet, V; Fazio, N; Hubner, RA; Jhaveri, K; Lahner, H; Li, Z; Martin, M; Maur, M; Tortora, G, 2021
)
0.62
" Pharmacokinetics of ALP, EVE and EXE was largely unchanged in combination with each other."( Alpelisib in combination with everolimus ± exemestane in solid tumours: Phase Ib randomised, open-label, multicentre study.
Ajipa, O; Andre, F; Beck, JT; Blumenstein, L; Curigliano, G; Donnet, V; Fazio, N; Hubner, RA; Jhaveri, K; Lahner, H; Li, Z; Martin, M; Maur, M; Tortora, G, 2021
)
0.62
" We conducted a phase 1b dose escalation trial (NCT01149356) of GSI RO4929097 with exemestane in patients with ERα+, metastatic breast cancer (MBC) STUDY OBJECTIVES: To determine the safety, tolerability and maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of RO4929097 when administered in combination with exemestane in patients with estrogen receptor positive metastatic breast cancer RESULTS: We enrolled 15 patients with MBC."( A Phase Ib Dose Escalation Trial of RO4929097 (a γ-secretase inhibitor) in Combination with Exemestane in Patients with ER + Metastatic Breast Cancer (MBC).
Abramson, VG; Del Valle, L; Ismail-Khan, R; Lush, RM; Majumder, S; Mayer, IA; Means-Powell, JA; Miele, L; Sanders, MS; Sorrentino, C; Tonetti, D, 2022
)
0.72
" Patients received a weekly intravenous infusion of xentuzumab (1000 mg) or placebo in combination with everolimus (10 mg/day orally) and exemestane (25 mg/day orally)."( XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Baktash, N; Biyukov, T; Blau, S; Burris, HA; Cortes, J; Díaz-Redondo, T; García-Sáenz, JÁ; Hart, L; Jañez, NM; Joaquim, A; Lemieux, J; Massey, D; Morales, S; Neven, P; Rugo, HS; Schmid, P, 2023
)
0.91
"While this study demonstrated that xentuzumab could be safely combined with everolimus and exemestane in patients with HR-positive/HER2-negative advanced breast cancer with non-visceral disease, there was no PFS benefit with the addition of xentuzumab."( XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease.
Baktash, N; Biyukov, T; Blau, S; Burris, HA; Cortes, J; Díaz-Redondo, T; García-Sáenz, JÁ; Hart, L; Jañez, NM; Joaquim, A; Lemieux, J; Massey, D; Morales, S; Neven, P; Rugo, HS; Schmid, P, 2023
)
0.91

Bioavailability

ExcerptReferenceRelevance
"The choice of treatment for elderly breast cancer patients needs particular care because the presence of physiological functional impairments can modify the drug bioavailability in an unpredictable manner."( Steroidal aromatase inhibitors in elderly patients.
Bajetta, E; Bichisao, E; Pozzi, P; Toffolatti, L; Zilembo, N, 2000
)
0.31
" It is well absorbed at a daily oral dose of 25 mg and produces significant suppression of aromatase and plasma estrogen levels without androgenic side effects."( Exemestane: a novel aromatase inactivator for breast cancer.
Jones, SA; Jones, SE, 2000
)
0.31
" To improve the solubility and bioavailability of exemestane, the self-microemulsifying drug delivery system (SMEDDS) was developed."( Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS).
Asati, D; Awasthi, A; Chaurasiya, A; Khar, RK; Mishra, G; Mukherjee, R; Singh, AK, 2009
)
0.35
"The aim of the present study was to develop proliposomal formulations to enhance the oral bioavailability of exemestane by improving solubility, dissolution and/or intestinal permeability."( Proliposomes of exemestane for improved oral delivery: formulation and in vitro evaluation using PAMPA, Caco-2 and rat intestine.
Betageri, GV; Hiremath, PS; Soppimath, KS, 2009
)
0.35
"The bioavailability of two exemestane tablet formulations was compared in 74 healthy post-menopausal females, aged 46 to 74 years, during a laboratory-blind, randomized, two-treatment, two-period, cross-over study under fed conditions."( Bioequivalence of exemestane in post-menopausal females.
Groenewoud, G; Nell, A; Potgieter, L; Seiler, D; Wettmarshausen, C, 2010
)
0.36
" EXE is orally active but its bioavailability is about 5% due to its low solubility in water and the extensive first pass effect."( Alternative oral exemestane formulation: improved dissolution and permeation.
Bilensoy, E; Sumnu, M; Vural, I; Yavuz, B, 2010
)
0.36
"Exemestane, a novel steroidal aromatase inactivator used in the treatment of advanced breast cancer has limited bioavailability (42%) due to poor solubility, extensive first-pass metabolism, and also the absorption is dependent on formulation type and food."( Enhanced bioavailability of exemestane via proliposomes based transdermal delivery.
Bandari, S; Jukanti, R; Sheela, S; Veerareddy, PR, 2011
)
0.37
" Data from large clinical trials have shown that the combination of everolimus , an orally bioavailable mTOR inhibitor with exemestane improves outcome of metastatic breast cancer resistant to non-steroidal aromatase inhibitors."( Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer.
Awada, A; Barthélémy, P; Gombos, A, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"Nanocrystals prepared by media milling technique were successful in improving the poor dissolution properties and oral bioavailability of exemestane."( Optimization of Performance Variables of Exemestane Nanosuspension Using Box-Behnken Design to Improve Dissolution and Oral Bioavailability.
Parmar, K; Shah, J, 2021
)
0.62
" It is crucial to develop strategies to increase the solubility and bioavailability of this drug."( Magnetic mesoporous silica nanoparticles as a theranostic approach for breast cancer: Loading and release of the poorly soluble drug exemestane.
Laranjeira, MS; Magalhães, AI; Monteiro, FJ; Ribeiro, TP; Santos, JAM; Silva, PC, 2022
)
0.72
" However, complex physicochemical characteristics of EXE limit its oral bioavailability (<10%) and anti-breast cancer efficacy."( Polymer-lipid hybrid nanoparticles of exemestane for improved oral bioavailability and anti-tumor efficacy: An extensive preclinical investigation.
Ahmad, S; Alam, M; Amin, S; Mir, SR; Perwez, A; Rizvi, MMA; Rizwanullah, M, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
" Thus, use of a steroidal and a non-steroidal aromatase inhibitors in concert may be one way to improve breast cancer treatment and may also provide important information to a better understanding of the dose-response relationship between estrogen suppression and clinical effects."( Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer.
Lønning, PE, 1998
)
0.3
" Moreover, exemestane has an acceptable tolerability profile and a convenient once daily oral dosage regimen."( Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett, D; Lamb, HM, 2000
)
0.31
" The dosing schedule for the Segment I study in rats, which included a postnatal component, was established to exclude exposure before and during parturition (by withdrawing treatment from GD 16 until the end of parturition)."( Reproductive toxicity of exemestane, an antitumoral aromatase inactivator, in rats and rabbits.
Beltrame, D; Brughera, M; di Salle, E; Giavini, E; Gunnarsson, K,
)
0.13
" This drug, at a dosage of 25 mg once daily, was shown to suppress in vivo aromatase activity by 97."( Current status and future potential role of exemestane in the treatment of early and advanced breast cancer (Review).
Crucitta, E; De Lena, M; Fornier, MN; Locopo, N; Lorusso, V; Silvestris, N, 2002
)
0.31
" Preclinical research has demonstrated that the estrogen dose-response curve for breast cancer cells can be shifted by modification of the estrogen environment."( Estrogen as therapy for breast cancer.
Ingle, JN, 2002
)
0.31
" Our findings suggest that a combination of paclitaxel with exemestane might be beneficial for the treatment of aromatase-positive gynecological cancer, because it may allow us to reduce the paclitaxel dosage and therefore the toxicity of the treatment."( Effects of a combination of exemestane and paclitaxel on human tumor cells in vitro.
Chen, D; Hackl, W; Ortmann, O; Treeck, O, 2004
)
0.32
" Dose-response experiments with chondrosarcoma cultured cells were done with estrogen, androstenedione, and exemestane."( Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma.
Baelde, HJ; Bovée, JV; Cleton-Jansen, AM; Hogendoorn, PC; Karperien, M; van Beerendonk, HM, 2005
)
0.33
"7 ng/mL) was observed at an average of 12 days within the first month and maintained at 12-15 ng/mL throughout the remainder of the dosing period."( Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor-positive advanced breast cancer.
McCormack, P; Sapunar, F, 2008
)
0.35
" Clinical awareness and early identification of such AEs by oncology nurses are essential to dosing (interruptions, reduction, and treatment discontinuation); quality of life; and, ultimately, patient outcomes."( Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial.
Peterson, ME, 2013
)
0.39
"The dosage effect of adjuvant treatments, cancer staging, genetic or environmental confounders associated with the risk of depressive disorders were not comprehensively evaluated."( Adjuvant treatments of breast cancer increase the risk of depressive disorders: A population-based study.
Chang, CH; Chen, SJ; Liu, CY, 2015
)
0.42
" Repeated injection of 5mg/kg letrozole in male rats produced mechanical, but not thermal, hypersensitivity that extinguished when drug dosing was stopped."( Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neurons.
Duarte, DB; Flockhart, DA; Robarge, JD; Shariati, B; Vasko, MR; Wang, R, 2016
)
0.43
"Due to toxic events, everolimus dosage was reduced to 5 mg in 27% of patients."( Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: A multicenter Italian experience.
Cortesi, E; D'Onofrio, L; Fabbri, MA; Gamucci, T; Giuliani, R; Iezzi, L; Magri, V; Mancini, ML; Marchetti, P; Mauri, M; Mentuccia, L; Moscetti, L; Natoli, C; Pizzuti, L; Ramponi, S; Roma, CL; Ruggeri, EM; Santini, D; Sini, V; Sperduti, I; Vaccaro, A; Vici, P, 2016
)
0.43
" A sample was collected 2 h after exemestane dosing at a 1- or 3-month study visit to measure drug concentration."( Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.
Desta, Z; Flockhart, DA; Gersch, CL; Hayes, DF; Henry, NL; Hertz, DL; Kidwell, KM; Rae, JM; Seewald, NJ; Skaar, TC; Stearns, V; Storniolo, AM, 2017
)
0.46
" We continued the standard dosage of corticosteroid treatment."( Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Goedegebuure, WJ; Hokken-Koelega, ACS, 2019
)
0.51
" We suggest continuing the same corticosteroid dosage during AI treatment and accepting higher serum androgen levels."( Aromatase Inhibitor as Treatment for Severely Advanced Bone Age in Congenital Adrenal Hyperplasia: A Case Report.
Goedegebuure, WJ; Hokken-Koelega, ACS, 2019
)
0.51
" Our results highlight that OPG urine concentrations were decreased 3 days after drug dosage (mean predosage OPG concentration, 61."( Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women.
Atchley, DH; Garcia, AP; Gurley, BJ; Hatvany, JB; Kamdem, LK; Murphy, MA, 2020
)
0.56
" In 21 patients a non-osseous biopsy obtained before dosing was useful for continuous scoring, which demonstrated upregulation of several proteins as compared to readings in corresponding primary tumour tissues."( PI3K pathway protein analyses in metastatic breast cancer patients receiving standard everolimus and exemestane.
Beelen, KJ; Boven, E; de Valk, B; Kruger, DT; Linn, SC; Nieuwenhuis, M; Opdam, M; Sanders, J; van der Noort, V, 2020
)
0.56
"This multicenter, presurgical, double-blind phase 2b randomized clinical trial evaluated 2 alternative dosing schedules of exemestane."( Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
Bedrosian, I; Bertelsen, BE; Bonanni, B; Brown, PH; Castile, T; Crew, KD; D'Amico, M; DeCensi, A; Dimond, E; Gandini, S; Guasone, F; Guerrieri-Gonzaga, A; Heckman-Stoddard, BM; Johansson, H; Kumar, NB; Lazzeroni, M; Lee, JJ; Mellgren, G; Serrano, D; Spinaci, S; Szabo, E; Thomas, P; Veronesi, P; Viale, G; Vornik, LA; Weber, D, 2023
)
0.91
"In this randomized clinical trial, exemestane, 25 mg, given 3 times weekly in compliant patients was noninferior to the once-daily dosage in decreasing serum estradiol."( Efficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor-Positive Breast Cancer: A Randomized Clinical Trial.
Bedrosian, I; Bertelsen, BE; Bonanni, B; Brown, PH; Castile, T; Crew, KD; D'Amico, M; DeCensi, A; Dimond, E; Gandini, S; Guasone, F; Guerrieri-Gonzaga, A; Heckman-Stoddard, BM; Johansson, H; Kumar, NB; Lazzeroni, M; Lee, JJ; Mellgren, G; Serrano, D; Spinaci, S; Szabo, E; Thomas, P; Veronesi, P; Viale, G; Vornik, LA; Weber, D, 2023
)
0.91
"The development and analysis of pharmaceutical formulations often involves the determination of multiple active ingredients in a dosage form."( Development and Method Validation of Design of Experiments-Optimized Tablet Formulation for Simultaneous Detection of Exemestane and Everolimus.
Kumar, A; Kurmi, BD; Singh, D,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
EC 1.14.14.14 (aromatase) inhibitorAn EC 1.14.14.* (oxidoreductase acting on paired donors, incorporating of 1 atom of oxygen, with reduced flavin or flavoprotein as one donor) inhibitor which interferes with the action of aromatase (EC 1.14.14.14) and so reduces production of estrogenic steroid hormones.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
17-oxo steroidAny oxo steroid carrying the oxo group at position 17.
3-oxo-Delta(1),Delta(4)-steroidA 3-oxo-Delta(1) steroid containing an additional double bond between positions 4 and 5.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency20.15490.173734.304761.8120AID1346859; AID1346924
PPM1D proteinHomo sapiens (human)Potency16.53880.00529.466132.9993AID1347411
SMAD family member 3Homo sapiens (human)Potency20.15490.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency12.38720.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency6.20690.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency8.24720.000221.22318,912.5098AID1259243; AID1259247; AID1259381; AID743035; AID743036; AID743040; AID743042; AID743053; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency39.81070.100022.9075100.0000AID485364
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency6.25330.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency9.43920.000417.946075.1148AID1346795
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency26.60320.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency29.84700.375827.485161.6524AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency20.36430.005428.02631,258.9301AID1346982; AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency16.51010.000229.305416,493.5996AID743069; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency27.54040.01238.964839.8107AID1645842
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency18.83220.001024.504861.6448AID743215
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency0.95210.023723.228263.5986AID743223
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency0.89130.035520.977089.1251AID504332
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency0.04220.001723.839378.1014AID743083
nuclear receptor subfamily 1, group I, member 2Rattus norvegicus (Norway rat)Potency31.62280.10009.191631.6228AID1346983
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency25.49050.000323.4451159.6830AID743065; AID743067
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency2.34680.000627.21521,122.0200AID743202; AID743219
Interferon betaHomo sapiens (human)Potency19.28920.00339.158239.8107AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency22.38720.009610.525035.4813AID1479145
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency27.54040.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)90.00000.11007.190310.0000AID1473738
AromataseHomo sapiens (human)IC50 (µMol)0.17010.00001.290410.0000AID1195644; AID1195646; AID1270822; AID1467355; AID1776977; AID1855795; AID1863225; AID704989
AromataseHomo sapiens (human)Ki0.01810.00000.60469.5010AID1270804; AID1270805
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (101)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (47)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (34)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (92)

Assay IDTitleYearJournalArticle
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1215997Drug metabolism assessed as human recombinant CYP2C8-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 20 2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1215988Drug metabolism assessed as human recombinant CYP2B6-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 5 u2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1195656Cytotoxicity against human placental microsome aromatase expressing human MCF7 cells assessed as reduction in cell viability at 10 to 15 uM after 3 to 6 days by MTT assay in presence of estradiol2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID1195657Cytotoxicity against human placental microsome aromatase expressing human MCF7 cells assessed as reduction in cell viability at 10 to 15 uM after 3 to 6 days by MTT assay in presence of testosterone2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1607296Inhibition of aromatase (unknown origin) assessed as inactivation constant2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215994Drug metabolism assessed as human recombinant CYP2C9-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 50 2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1270822Inhibition of aromatase (unknown origin)2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1195645Inhibition of human placental microsome aromatase expressed in human MCF7 cells using [1beta-3H] androstenedione as substrate at 10 uM after 1 hr by liquid scintillation counting2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID1299175Inhibition of aromatase in human placental microsomes using [1beta-3H]-androstenedione as substrate assessed as tritiated H2O release at 1 uM after 15 mins by liquid scintillation counting method relative to control2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
AID503315Antiproliferative activity against human PC3 cells at 1.5 uM after 120 hrs by MTT assay relative to DMSO2006Nature chemical biology, Jun, Volume: 2, Issue:6
Identifying off-target effects and hidden phenotypes of drugs in human cells.
AID1593297Inhibition of human placental microsome aromatase at 2 uM using [1beta3H]-androstenedione as substrate measured after 15 mins in presence of NADPH by liquid scintillation counting method relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
C-6α- vs C-7α-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships.
AID1195644Inhibition of human placental microsome aromatase using [1beta-3H] androstenedione as substrate after 15 mins by liquid scintillation counting2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID1215987Drug metabolism assessed as human recombinant CYP3A4-mediated 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 1 uM ketoconazole2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1593299Inhibition of human placental microsome aromatase expressed in human MCF7 cells at 10 uM using [1beta3H]-androstenedione as substrate measured after 1 hr in presence of progesterone relative to control2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
C-6α- vs C-7α-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1467355Inhibition of CYP19 in human placental microsome using [1beta-3H]-androstenedione as substrate after 15 mins in presence of NADPH by liquid scintillation counter method2017Bioorganic & medicinal chemistry letters, 06-15, Volume: 27, Issue:12
Evaluation of synthesized coumarin derivatives on aromatase inhibitory activity.
AID1215996Drug metabolism assessed as human recombinant CYP2C19-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 5 2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1863225Inhibition of aromatase in human JEG-3 cells using Androst-4-ene-3,17-dione as substrate incubated for 1 hr and measured by BCA assay2022European journal of medicinal chemistry, Oct-05, Volume: 2404th generation nonsteroidal aromatase inhibitors: An iterative SAR-guided design, synthesis, and biological evaluation towards picomolar dual binding inhibitors.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1195643Inhibition of human placental microsome aromatase using [1beta-3H] androstenedione as substrate at 2 uM after 15 mins by liquid scintillation counting2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID1776977Inhibition of aromatase (unknown origin)2021Journal of natural products, 06-25, Volume: 84, Issue:6
Diterpenoids with Aromatase Inhibitory Activity from the Rhizomes of
AID1195646Inhibition of human placental microsome aromatase expressed in human MCF7 cells using [1beta-3H] androstenedione as substrate after 1 hr by liquid scintillation counting2014European journal of medicinal chemistry, Nov-24, Volume: 87Exemestane metabolites: Synthesis, stereochemical elucidation, biochemical activity and anti-proliferative effects in a hormone-dependent breast cancer cell line.
AID1299178Inhibition of human placental aromatase expressed in human MCF7 cells using [1beta-3H]-androstenedione as substrate assessed as tritiated H2O release at 10 uM after 1 hr by liquid scintillation counting method in presence of progesterone relative to contr2016Bioorganic & medicinal chemistry, 06-15, Volume: 24, Issue:12
Exploring new chemical functionalities to improve aromatase inhibition of steroids.
AID1607295Inhibition of human placental microsome aromatase using [3H]androstenedione as substrate preincubated for 32 mins in presence of NADPH followed by substrate addition and measured after 10 mins2020Journal of medicinal chemistry, 05-14, Volume: 63, Issue:9
Design and Characterization of the First Selective and Potent Mechanism-Based Inhibitor of Cytochrome P450 4Z1.
AID1593307Competitive inhibition of human placental microsome aromatase using varying levels of [1beta2beta3H]-androstenedione as substrate2019Journal of medicinal chemistry, 04-11, Volume: 62, Issue:7
C-6α- vs C-7α-Substituted Steroidal Aromatase Inhibitors: Which Is Better? Synthesis, Biochemical Evaluation, Docking Studies, and Structure-Activity Relationships.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1215986Drug metabolism assessed as human recombinant CYP1A2-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 20 2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1270804Irreversible inhibition of human aromatase extracted from placental microsomes2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1215985Drug metabolism assessed as human recombinant CYP3A4-mediated 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 50 uM troleandomycin2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID704989Inhibition of human placental aromatase using [3H]-1beta-androstenedione as substrate after 16 hrs by [3H]-water method2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Novel aromatase inhibitors by structure-guided design.
AID1270805Competitive inhibition of human aromatase extracted from placental microsomes2015European journal of medicinal chemistry, Nov-13, Volume: 105Developing steroidal aromatase inhibitors-an effective armament to win the battle against breast cancer.
AID1215999Drug metabolism assessed as human recombinant CYP2E1-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 50 2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1855795Inhibition of aromatase in human breast tumor2022European journal of medicinal chemistry, Nov-05, Volume: 241An overview on Estrogen receptors signaling and its ligands in breast cancer.
AID1215998Drug metabolism assessed as human recombinant CYP2D6-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 1 u2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1216017Drug metabolism in human liver microsomes assessed as retention time at 300 uM after 10 mins by HPLC with UV analysis2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1215995Drug metabolism assessed as human recombinant CYP2B6-mediated 17-hydroexemestane and 6-Hydroxymethylexemestane formation assessed as inhibition of metabolite formation at 10 uM after 10 mins by Michaelis-Menten saturation curve analysis in presence of 5 u2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
In vitro cytochrome P450-mediated metabolism of exemestane.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID704988Cytotoxicity against human MCF7a cells expressing Tet-off-3betaHSD1-Arom assessed as inhibition of TST-stimulated cell proliferation measured after 10 days2012Journal of medicinal chemistry, Oct-11, Volume: 55, Issue:19
Novel aromatase inhibitors by structure-guided design.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345280Human CYP19A1 (CYP11, CYP17, CYP19, CYP20 and CYP21 families)1985Diabetic medicine : a journal of the British Diabetic Association, Jul, Volume: 2, Issue:4
Glomerular hyperfiltration in diabetes mellitus.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (860)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (0.58)18.7374
1990's24 (2.79)18.2507
2000's293 (34.07)29.6817
2010's444 (51.63)24.3611
2020's94 (10.93)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 48.49

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index48.49 (24.57)
Research Supply Index7.04 (2.92)
Research Growth Index5.77 (4.65)
Search Engine Demand Index79.51 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (48.49)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials245 (27.31%)5.53%
Reviews195 (21.74%)6.00%
Case Studies62 (6.91%)4.05%
Observational8 (0.89%)0.25%
Other387 (43.14%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]